S1 Table. Expression level of each 27 tissue markers using immunohistochemistry

Tissue markers	Positive expression, n (%)	Median	Range	IQR
CA9	87 (53.70)	20	0-290	0-120
CD8	84 (51.85)	20	0-210	0-30
CD31	143 (88.27)	210	0-300	110-220
CD34	162 (100)	60	20-300	30-210
CD44	134 (82.72)	150	0-300	10-290
C-erb	21 (12.96)	0	0-300	0-0
CK5-6	98 (60.49)	10	0-300	0-270
CK20	78 (48.15)	0	0-300	0-270
C-myc	122 (75.31)	30	0-300	10-260
COX2	162 (100)	280	70-300	250-300
Cyclin D1	113 (69.75)	45	0-300	0-270
Cyclin D2	161 (99.38)	280	0-300	250-300
E-cadherin	137 (84.57)	150	0-300	20-280
ERCC1	123 (75.93)	265	0-300	10-300
Hif-1	17 (10.49)	0	0-280	0-0
Hif-2	62 (38.27)	0	0-280	0-20
HMWCK	95 (58.64)	30	0-300	0-270
Ki-67	85 (52.47)	10	0-100	0-20
LMWCK	107 (66.05)	40	0-300	0-270
p53	95 (68.35)	250	0-300	0-300
PDGFR	157 (96.91)	290	0-300	160-300
PD-L1	5 (3.09)	0	0-40	0-0
PSM	3 (1.85)	0	0-140	0-0
PTEN	124 (76.54)	150	0-300	20-290
Rb loss	107 (66.05)	150	0-300	0-290
SMA	147 (90.74)	30	0-300	20-150
VEGF	147 (90.74)	250	0-300	130-290

Range, minimum-maximum; IQR, interquartile range (Q1-Q3). C-erb, epidermal growth factor receptor; CK, cytokeratin; COX2, cytochrome c oxidase II; ERCC1, ERCC excision repair 1; HMWCK, high-molecular-weight heparin; LMWCK, low-molecular-weight heparin; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed cell death 1 ligand; PSM, prostate-specific membrane antigen; Rb, retinoblastoma; SMA, smooth muscle actin; VEGF, vascular endothelial growth factor.